Skip to main content

Spravato® Treatment in Oklahoma City, OK

Spravato® Treatment is available at 4013 NW Expressway, Suite 105 in Oklahoma City, OK.

LifeStance Health Oklahoma City, OK

4013 NW Expressway, Suite 105
Oklahoma City, OK 73116

Get Directions

Billing Phone:425-654-7020
Fax:405-378-2776

Hours of Operation

Monday7:30 AM - 4:00 PM
Tuesday7:30 AM - 4:00 PM
Wednesday7:30 AM - 4:00 PM
Thursday7:30 AM - 4:00 PM
Friday7:30 AM - 4:00 PM
SaturdayClosed
SundayClosed

Spravato® Treatments At LifeStance

Spravato® (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression (TRD) and depressive symptoms of major depressive disorder (MDD) with suicidal thoughts or actions. Spravato® treatments are administered under the supervision of a healthcare provider in a safe, comfortable, and supportive clinic environment.

  • check-circle-whiteFDA-approved nasal spray
  • check-circle-whiteFor depression that hasn't responded to antidepressants
  • check-circle-whiteAdministered in-office under provider supervision
  • check-circle-whiteCovered by most insurance
  • check-circle-whiteWorks differently than traditional antidepressants

Mental Health Providers that offer Spravato® Treatment in Oklahoma City, Oklahoma

In-office appointments
In-office & online appointments

Our Oklahoma Locations

We currently offer Spravato® treatments in select Oklahoma offices. Check for a location near you.

Oklahoma City

4013 NW Expressway, Suite 105,
Oklahoma City, OK 73116

405-906-2695

Edmond

2908 Astoria Way, Suite 150,
Edmond, OK 73034

405-378-2727

Moore

1113 SW 30th Ct, Suite B,
Moore, OK 73160

405-378-2727

Tulsa

9228 S Mingo Rd, Suite 101,
Tulsa, OK 74133

918-727-2157

Spravato® Treatment in Oklahoma City, Oklahoma FAQ

Researchers believe Spravato® works to treat depression by targeting the NMDA receptor and glutamate neurotransmitter system in your brain. Scientific studies have illuminated the importance of NMDA/glutamate in modulating mood, behavior, memory, and learning.

Yes. Spravato® was approved by the FDA in 2019. It is under patent until 2024, after which there will likely be generic equivalents on the market.

No. Spravato® should be taken in conjunction with an oral antidepressant. Insurance companies require a patient to be prescribed an oral antidepressant prior to approving treatment coverage. Spravato® is intended to supplement but not replace your current anti-depression treatment.

Research studies show an efficacy of 33-60% depending on the duration of treatment.

Addiction to or physical dependence on Spravato® was not found in over 1700 patients included in clinical trials. It is unlikely that Spravato® taken at the doses and frequency used to treat mood symptoms will lead to any dependence or addiction.

Yes. The efficacy of Spravato® has been evaluated in short-term clinical trials and one longer-term maintenance-of-effect trial. In one of the short-term studies, Spravato® demonstrated a statistically significant effect on the severity of depression. In the maintenance trial, patients who continued treatment with Spravato® plus an oral antidepressant experienced a statistically significant longer time to relapse of depressive symptoms.

In a clinical trial for Spravato®, 65% of patients responded to treatment, achieving a 50% or greater reduction in depressive symptoms and 32% were in remission, these patients did not meet criteria for depression. In addition, patients who had responded to Spravato® were 71% less likely to relapse if they continued the medication and if they had been in remission, they were 51% less likely to relapse.

Find Mental Health Care Clinics & Services Near You